Treatment patterns for patients with treatment resistant depression in France using nationwide claims database

Authors

Vimont Alexandre[1], Biscond Margot[1], Leleu Henri[1], Llorca Pierre-Michel[2]

Affiliations

1. Public Health Expertise, Paris, France

2. Department of Psychiatry, CHU Clermont-Ferrand, CNRS, Clermont Auvergne INP, Institut Pascal (UMR 6602), University of Clermont Auvergne, 63000 Clermont-Ferrand, France

Funding

This study was fully funded by Public Health Expertise

Author Contributions

Conceptualization: A.V, M.B and P.M.L. Statistical analyses: A.V, M.B. Writing—Original Draft Preparation: A.V, M.B; Writing—Review and Editing: A.V, M.B and P.M.L. All authors have read and agreed to the published version of the manuscript.

Informed Consent Statement

Not applicable

Data Availability Statement

Data are not publicly available.

Conflict of interest

Pierre-Michel Llorca has received personal fees and/or non-financial support from Eisai, Ethypharm, Janssen, Lundbeck, MSD, Neuraxpharm, Novartis, Otsuka, Roche, Rovi, and Sanofi.

The other authors declare no conflicts of interest.

Abstract

Background: Prevalence of TRD varied widely across studies. Several treatment strategies exist to manage patient with Treatment-Resistant Depression (TRD) but evidence from real-world data is scarce. Investigating their use in real life is important to understand national prescribing practices and to refine prevalence estimation.

Method: All adult patients (≥ 18 years) with a TRD episode for the year 2019 were identified in a sample of four French regions accounting for 27% of national individuals. After exclusion of psychotic or bipolar affective disorders, Parkinson's disease, and dementia, a TRD episode was defined 1/ by three successive sequences of different AD, or 2/ by the dispensing of several different AD together, or 3/ by an AD with a potentiator (lithium, antiepileptic drugs, antipsychotic drugs) over the same treatment period. The prevalence rate was estimated for the year 2019 and treatment patterns were described by treatment class associations and molecules.

Results: For the year 2019, 66,810 patients were identified with a TRD episode, accounting for 23.9% of all patients treated for depression. The mean age was 56 years (±15.9) with 63.7% of women. Standardized prevalence of TRD was estimated at 35.1 per 10 000 patients, and 25.8 per 10,000 patients when excluding patients probably treated for another primary diagnosis than depression. Association of AD and antipsychotic was the most frequently used strategy, with SSRIs and second-generation antipsychotics being most prescribed.

Conclusion: In conclusion, this study provides the robust population-based estimates of the prevalence of TRD in the French population. Description of treatment patterns highlight the widespread use of second-generation antipsychotics as potentiator of AD medication complemented with anxiolytics.

Keywords

Major depression disorder, Treatment resistant, Claims database, Real-world data, Prevalence, Treatment patterns.

Introduction

Major depressive disorder (MDD) is highly prevalent in the global population, affecting 5.1% of females and 3.6% of men, varying according to age and region (1) . In France, 1.65% to 7.5% of the population is concerned by MDD (2) and 12.5% of adults would experience a major depressive episode (MDE) in their last 12 months (3). Depression is a major public health priority since it is associated with a high economic burden (4), with an important risk of suicide, especially in adolescents and young adults (5).

Treatment options for MDE include psychotherapy, pharmacotherapy, and neuromodulation strategies such as repeated transcranial magnetic stimulation (rTMS) and electroconvulsive therapy (ECT) (6). Treatment recommendations exist in France to support decision making to physicians to improve the chances of achieving a response (7).

Although the management of MDE is structured with demonstrated antidepressants and psychotherapies efficacy, it is well known that these treatments have limited efficacy in some patients. Studies estimated between 15% and 30% of patients with MDD who do not respond to a proper sequence of pharmacotherapies. A consensual definition states that patients who failed to respond adequately after the consecutive use of at least two antidepressants (ADs) are considered treatment-resistant to depression (TRD)(7). AD could whether or not be from different pharmacological class or being combined, but at doses and durations that would normally be effective, administered for 6 to 8 weeks to a patient believed to be adherent.

Recommendations suggest that sequence of pharmacotherapies may include the combination of two individual ADs in case of non-response to a first one or a combination of an AD potentiated by other medications such as lithium, antiepileptics, antipsychotics or thyroid hormones (ref). However, the use of these combinations from real world evidence remains scarce (8,9).

Although clinical characteristics of TRD patients have been widely described (10), the epidemiologic situation and the treatment strategies used in real-world remain poorly documented since definitions were highly heterogeneous across studies, especially regarding the number or the type of antidepressants (AD) to consider before being considered TRD. However, it is well known that the clinical and economic burden is amplified among TRD patients, who are associated to increased impairment and morbidity, and less likely to respond to a subsequent sequence of therapy (11).

We conducted a retrospective large-scale and population-based study with the French nationwide claims database to estimate prevalence of TRD and to provide evidence on treatment strategies used from real-world data.

Methods

Data source

This study was conducted from a sample of the French nationwide claims database (SNDS database) under the regulatory approval MLD/TDC/AR 211497 (CNIL reference number). Since the entire population from the SNDS is not made available for research (12), the sample of four regions was used and populated of individuals with at least one delivery of AD

during the period 2015 to 2019. Regions including Bretagne, Normandie, Loire-Atlantique, and Grand-Est accounting for 27% of the national population. Regions were selected based on their heterogeneity in terms of incidence rates of MDD and care-settings utilization (hospital and outpatient psychiatric wards) to better be representative (13).

This real-world database is managed by National Health Insurance (NHI) which ensures completeness of the sample. In France, a compulsory public insurance scheme is applied to all individuals to cover the majority of costs. Information on private insurance schemes that patients subscribe to cover the complementary part was not available. The database included information on demographics, medical history, diagnoses and procedures related to in-hospital admissions, prescriptions, laboratory assays, and date of death (12).

The database offers different alternatives to identify chronic diseases. First, long-term disease (LTD) coverage for all medical expenses is always related to some chronic diseases (LTD), such as MDD or dementia. Second, hospital diagnoses include primary and secondary diagnoses coded according to the ICD-10 and allow identification of chronic diseases or isolated episode without distinction, such as anxiety disorders or alcohol dependency. Third, pharmacy claims provide evidence for treatment sequencing and adherence in the scope of their approved indications.

Study design

This study included all adults with an episode of TRD identified between 1 January 2019 and 31 December 2019. Identification of TRD was based on outpatient deliveries of AD and its potentiators, complemented by other psychotic diagnoses identified either through LTD coverage either during inpatient admissions. Patients with ongoing LTD or history of admission for chronic psychotic disorder, bipolar affective disorder, Parkinson's disease or dementia within the 5-year study period were excluded (Codes in **Supplementary file 1**). These chronic diseases were essentially identified through LTD and admission diagnoses. Anxiety disorders used in sensibility analyses were captured with treatment associations since the database did not allow distinction between isolated and characterized episodes.

TRD episodes during the year 2019 were identified using the standard definition of TRD and the recommended treatment strategies in France (7). TRD was defined by the succession of 3 treatment strategies (**Figure 1**), including AD monotherapy, combination of 2 ADs or more, or combination of AD with a potentiator, including lithium, antiepileptic drugs without a prior history of epilepsy, antipsychotic drugs and thyroid hormones without a prior history of hypothyroidism.

A treatment strategy was considered as such if treatment deliveries covered at least 3-week treatment duration. For longer treatment duration an adequate treatment adherence was required, assessed by a Medication Possession Ratio (MPR) ≥ 80% for each treatment strategy. The MPR measures the proportion of days covered by treatment deliveries during the period between the first drug reimbursements of two successive treatment sequences. A recovery from TRD episode was assumed when no delivery of any AD medication was observed during a 6-month period. Thus, a subsequent TRD episode was considered when discontinuation of therapy for at least 6 months was previously observed (**Figure 2**). Index date for TRD was defined at initiation of the first treatment strategy.

Statistical analyses

A descriptive analysis of prevalent TRD patients was conducted for the year 2019. Historical period (2015-2018) was used to identified other chronic psychotic disorders and to construct sequence of treatment. Characteristics included sex, age, duration of long-term coverage if any, duration of TRD episode (treatment duration for the current TRD episode), other psychiatric condition, and proportion of episode initiated during the year 2019.

The prevalence was estimated for the year 2019 and extrapolated to the national level, with age and gender standardization. Prevalence was calculated by weighting the gender- and age-specific number of patients observed in the study population sample by the gender and age structure of the national population (14). A sensitivity analysis on the prevalence calculation was conducted by excluding patients being prescribed AD probably for other primary diagnosis than MDD, such as anxiety disorders, alcohol dependency with comorbid depression, or chronic pain. These specific conditions were identified based on concomitant treatment deliveries with AD: anxiety disorders, alcohol dependency with nalmefene (the only reimbursed drug for this disorder in France), and chronic pain with opioids.

Patients potentially treated for a primary diagnosis of anxiety disorders were defined as patients with AD monotherapy (not potentialized) that holds an indication for anxiety disorders. Among these patients, proportion of patients with concomitantly prescribed anxiolytics (benzodiazepines, H1-receptor antagonist as hydroxyzine, and phenothiazine as cyamemazine) were reported. Cyamemazine is a first-generation antipsychotic that holds additional approval in France for acute or long-term treatment of anxiety or aggressiveness.

Treatment strategies and molecules delivered on the last observed prescription during TRD episode for the year 2019 were reported for the overall population and stratified by group of age below and over 65 years.

Results

Prevalence of TRD

Among the four included regions, a total of 452,800 patients had at least one delivery of AD during the year 2019 (**Additional file 1**). Of these, 132,435 (29.3%) were excluded because they were associated to a chronic psychotic disorder (n=44,289, 11.1%), chronic Parkinson's disease (n=10,429, 2.6%), dementia (n=37,185, 9.3%), or bipolar disorder (n=39,147, 9.8%). The remaining patients were assumed to be treated for MDD (n=279,479), of which 23.9% (n=66,810) were identified with an ongoing TRD episode during 2019.

The corresponding standardized prevalence at national level was estimated at 35.4 per 10,000 patients, corresponding to 238,161 patients (31.5 for patients between 18 and 65, and 68.3 per 10,000 for patients over 65 years) when extrapolated to the French population.

Since it was not possible to identify exactly the context of use of treatment, a sensitivity analysis was conducted and presented in the following section by excluding some of these patients for the prevalence estimation.

Description of the population

Patients were predominantly women (63.7%), and 29.9% (n=19,975) were more than 65 years of age (**In conclusion**, this study provides the robust population-based estimates of the prevalence of TRD in the French population. Description of treatment patterns highlight the widespread use of second-generation antipsychotics as potentiator of AD medication complemented with anxiolytics.

References

1. WHO | Regional Office for Africa [Internet]. 2023 [cité 21 déc 2023]. Depression and Other Common Mental Disorders: Global Health Estimates (2017). Disponible sur: https://www.afro.who.int/publications/depression-and-other-common-mental-disorders-global-health-estimates-2017

2. Filipovic-Pierucci A, Samson S, Fagot JP, Fagot-Campagna A. Estimating the prevalence of depression associated with healthcare use in France using administrative databases. BMC Psychiatry. 3 janv 2017;17(1):1.

3. SPF. Prévalence des épisodes dépressifs en France chez les 18-85 ans : résultats du Baromètre santé 2021 [Internet]. [cité 21 déc 2023]. Disponible sur: https://www.santepubliquefrance.fr/import/prevalence-des-episodes-depressifs-en-france-chez-les-18-85-ans-resultats-du-barometre-sante-2021

4. Johnston KM, Powell LC, Anderson IM, Szabo S, Cline S. The burden of treatment-resistant depression: A systematic review of the economic and quality of life literature. J Affect Disord. 1 janv 2019;242:195‑210.

5. McLafferty M, Brown N, McHugh R, Ward C, Stevenson A, McBride L, et al. Depression, anxiety and suicidal behaviour among college students: Comparisons pre-COVID-19 and during the pandemic. Psychiatry Res Commun. déc 2021;1(2):100012.

6. McIntyre RS, Alsuwaidan M, Baune BT, Berk M, Demyttenaere K, Goldberg JF, et al. Treatment-resistant depression: definition, prevalence, detection, management, and investigational interventions. World Psychiatry. oct 2023;22(3):394‑412.

7. Charpeaud T, Genty JB, Destouches S, Yrondi A, Lancrenon S, Alaïli N, et al. Prise en charge des troubles dépressifs résistants : recommandations françaises formalisées par des experts de l'AFPBN et de la fondation FondaMental. L'Encéphale. 1 sept 2017;43(4, Supplement):S1‑24.

8. Masson E. EM-Consulte. [cité 21 déc 2023]. Dépression résistante : les stratégies de potentialisation. Disponible sur: https://www.em-consulte.com/article/1048362

9. Masson E. EM-Consulte. [cité 21 déc 2023]. Dépression résistante : les stratégies de changement et d'association de médicaments antidépresseurs. Disponible sur: https://www.em-consulte.com/article/1048361

10. Mrazek DA, Hornberger JC, Altar CA, Degtiar I. A review of the clinical, economic, and societal burden of treatment-resistant depression: 1996-2013. Psychiatr Serv. 1 août 2014;65(8):977‑87.

11. Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. nov 2006;163(11):1905‑17.

12. Tuppin P, Rudant J, Constantinou P, Gastaldi-Ménager C, Rachas A, de Roquefeuil L, et al. Value of a national administrative database to guide public decisions: From the système national d'information interrégimes de l'Assurance Maladie (SNIIRAM) to the système national des données de santé (SNDS) in France. Rev Epidemiol Sante Publique. oct 2017;65 Suppl 4:S149‑67.

13. Atlas de la santé mentale en France [Internet]. [cité 21 déc 2023]. Disponible sur: https://santementale.atlasante.fr/#c=home

14. Estimation de la population au 1er janvier 2023 | Insee [Internet]. [cité 21 déc 2023]. Disponible sur: https://www.insee.fr/fr/statistiques/1893198

15. Kubitz N, Mehra M, Potluri RC, Garg N, Cossrow N. Characterization of treatment resistant depression episodes in a cohort of patients from a US commercial claims database. PLoS One. 2013;8(10):e76882.

16. Fife D, Feng Y, Wang MYH, Chang CJ, Liu CY, Juang HT, et al. Epidemiology of pharmaceutically treated depression and treatment resistant depression in Taiwan. Psychiatry Res. juin 2017;252:277‑83.

17. Gronemann FH, Jorgensen MB, Nordentoft M, Andersen PK, Osler M. Incidence of, Risk Factors for, and Changes Over Time in Treatment-Resistant Depression in Denmark: A Register-Based Cohort Study. J Clin Psychiatry. 29 mai 2018;79(4):17m11845.

18. Bosco-Lévy P, Grelaud A, Blin P, Astruc B, Falissard B, Llorca PM, et al. Treatment resistant depression incidence and prevalence using the French nationwide claims database. Pharmacoepidemiol Drug Saf. févr 2021;30(2):169‑77.

19. Conway CR, Gebara MA, Walker MC, Lessov-Schlaggar CN, Janski AM, Chibnall JT, et al. Clinical characteristics and management of treatment-resistant depression. J Clin Psychiatry. nov 2015;76(11):1569‑70.

20. Mahlich J, Tsukazawa S, Wiegand F. Estimating Prevalence and Healthcare Utilization for Treatment-Resistant Depression in Japan: A Retrospective Claims Database Study. Drugs Real World Outcomes. mars 2018;5(1):35‑43.

21. Al-Harbi KS. Treatment-resistant depression: therapeutic trends, challenges, and future directions. Patient Prefer Adherence. 2012;6:369‑88.

22. Seroquel XR - referral | European Medicines Agency [Internet]. [cité 11 janv 2024]. Disponible sur: https://www.ema.europa.eu/en/medicines/human/referrals/seroquel-xr

23. Hepner KA, Rowe M, Rost K, Hickey SC, Sherbourne CD, Ford DE, et al. The effect of adherence to practice guidelines on depression outcomes. Ann Intern Med. 4 sept 2007;147(5):320‑9.



Figure 1 Illustration of initiation date for a treatment strategy



Figure 2 Illustration of patient inclusion and exclusion for each strategy

Table 1). Most patients (64.5%) had long-term disease coverage (LTD) for depressive disorder for an average duration of 9 years (SD: 9.2). A minority of patient had history of addictive disorder (14.1%) within the last two years (2017-2018), related to alcohol (11.2%), tobacco (3.4%) or other (4.1%). On top, 2.5% of patients (n=1,655) were concomitantly (same prescription) receiving treatment for alcohol dependency in 2019 (nalmefene), so as other co-treatments including anxiolytics (41.4%) and opioids (8.6%).

The majority of patients were already under AD in 2015 (54.3%) and 12.7% initiated AD in 2019 (no AD delivery within the 4-year period of 2015-2018). Excluding patients who initiated AD in 2015 or before, the average duration of treatment for the TRD episode identified in 2019 was 20 months (SD=13.5 months).

Description of treatment strategies

Treatment strategies used in TRD patients in 2019 are presented in **Table 2**. Overall, 31.9% of TRD patients were treated with AD monotherapy (after failure of two different classes of AD), mainly SSRIs. Combination therapy was used in 68.6% of TRD patients, with 58.7% receiving either 2 ADs (4.4%) or AD combined with a potentiator, either an antipsychotic (35.4%) or an antiepileptic (18.4%). Some patients were receiving 3 classes or more of ADs and a

potentiator (9.4%). Overall, combination of one or several ADs associated to an antipsychotic was the most prevalent strategy with 38.3% of TRD patients, including XXX followed by AD monotherapy (31.9%) after failure of two previous classes.

According to patient age, treatment strategies were relatively similar except for the association of AD with an epileptic treatment which was more prescribed in patients over 65 years old (23.0% vs 16.4%).

Description of molecules

The proportion of each molecule used in TRD patients is presented in **Table 3**. AD molecules most prescribed were venlafaxine (N= 14,064, 21.1%), paroxetine (N= 9,108, 13.6%), mirtazapine (N=7,478, 11.2%), escitalopram (N= 6,663, 10.0%) and fluoxetine (N=6,042, 9.0%).

Potentiator most prescribed was quetiapine (n=6,174, 9.2%), followed by aripiprazole (n=4,736, 7.1%), olanzapine (n=4,174, 6.2%) and risperidone (n=3,727, 5.6%). Cyamemazine was also frequently used in TRD patients (n=7,914, 11,.8%).

Proportions between age groups were relatively similar, except for the associations of AD with quetiapine, aripiprazole and venlafaxine that were les prescribed in patients over 65 years.

Sensitivity analyses for prevalence estimation

The use of specific concomitant treatments (concomitant prescription) with an AD and/or potentiator are presented in **Table 4**. Patients being prescribed AD that holds anxiety disorders approval and associated to anxiolytics or cyamemazine were assumed to be probably treated for a primary diagnosis of anxiety disorder. Overall, 23.6% of TRD patients (n=15,759) were probably treated for another primary diagnosis, 14% (n=9,342) for an anxiety disorder, 8.6% (n=5,776) for neuropathic pain, and 2.5% (n=1,655) for alcohol dependency. Excluding these patients, the annual prevalence was estimated at 25.8 per 10,000 persons.

Among the TRD population, most patients were prescribed anxiolytics (55.8%, n=37,309), and for the majority associated to a potentialized strategy (37.5%, n=25,036).

Proportions between age groups were relatively similar, with slightly higher prevalence of anxiety disorder and alcohol dependency in patients above 65 years.

Discussion

To our knowledge, very few studies focusing on treatment resistant depression exist, especially studies based on large-scale population from real-world setting. We aimed at identifying TRD patients to estimate the prevalence of TRD and to provide evidence on treatment strategies from real-world data.

In our study, prevalence of TRD within the population treated with AD for MDD was 23.9%. While it is commonly stated that TRD is affecting approximately 30% of patients with MDD, differences in the definition of TRD resulted in highly variable estimation of its prevalence. Our finding was slightly lower than the existing literature where prevalence of resistant depression estimated in several studies ranged from 6.6% to 35% in patients with MDD

(11,15–17). In a more recent international review (6), authors calculated prevalence of TRD from the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial (11) and estimated that about 55% of patients with MDD had failed 2 treatment strategies in a short time period.

Estimates in our study corresponded to a sex- and age-standardized prevalence of 35.1 per 10,000 patients. When excluding patients potentially treated for another primary diagnosis, the annual prevalence was estimated at 25.8 per 10,000 persons. In France, according to last population-based studies in depression(2), the expected prevalence of TRD in France should be from 10 to 262 per 10 000 patients. In a similar study, conducted from a sample of the French national claims database, prevalence was estimated to range between 25.8 and 37.6 per 10,000 patients (18).

The majority of patients were women (63.7%), especially in the patients over 65 years (72.1%) with average disease duration of 9 years, and average treatment duration for a TRD episode of 20 months. These findings were similar to studies conducted in patients with depressive disorders identified from the French national healthcare claims (56.7 years vs 54.6 years, and 64% versus 66%)(2). Similarly, duration of TRD episode was consistent with existing literature.

Description of TRD strategies showed that combination of an AD and an antipsychotic was the most frequently used strategy, before AD monotherapy. SSRIs were the AD most prescribed in TRD whatever the strategy, which is consistent with the literature (19–21). Of the potentiators, quetiapine, a second generation antipsychotic, was the most prescribed. In Europe, quetiapine holds approval for using as add-on to ongoing treatment for major depressive episodes in patients with MDD who have had sub-optimal response to treatment with other ADs (22).

This study has several strengths. The first relied on the high populational level of the database, which included all individuals under AD treatment from 4 entire regions of France, accounting for 27% of the French individuals. On top, the SNDS database gathers all healthcare claims, allowing traceability of all reimbursed treatments.

Second, the TRD identification algorithm was developed to reflect the recent published recommendations of national experts (7). Although, guidelines do not specify prioritization of strategies, our findings suggest some predominant stages. We found that 30% of TRD patients were treated with AD monotherapy, with more recent duration of disease (median duration of 4 years) compared to combination treatment (70%) associated to longer disease (median duration of 7 years). This suggest that TRD patients tends to be treated with AD monotherapy at early stage, while combining treatment with potentiator later on, especially with antipsychotics. In this context, an expert-panel study conducted in the US evaluating adherence to guideline of primary care physicians pointed out the high need for improvement of treatment adjustment in nonresponsive patients, among other quality indicators (23).

Third, we provided estimation based on a more stringent definition to minimize overestimation of prevalence estimates. We intended to identify other potential primary diagnoses than MDD that a patient could be treated for with an AD-based strategy, such as anxiety disorders, chronic pain or alcohol dependency, to exclude them from the prevalence

calculation. Unobserved other primary diagnoses can be confounding factors in a study carried out on a claims database which could leading to biased prevalence estimates. In our sensitivity analysis, primary indication for anxiety disorders was considered probable when an AD holding this indication was concomitantly prescribed with anxiolytics, or cyamemazine. When excluding these groups of patients, 23.6% of the TRD initial population, prevalence of TRD was estimated at 27.4 per 10,000 patients.

Our study presented several limitations. First, the reason of treatment is not clearly stated in the database, so that AD could have been used for another primary indication than MDD. Several conditions identified essentially through LTD and admissions were initially excluded from the overall population, such as bipolar disorder, chronic psychotic disorder, Parkinson's disease and dementia, to confirm the underlying depressive condition.

Also, specific conditions were intended to be identified based on concomitant treatment deliveries for anxiety disorders, chronic pain or alcohol dependency with comorbid depression. In current practices, prescription of symptomatic anxiolytics associated to AD is frequently used for isolated anxious episode to improve patient health state but the database did not allow to differentiate them from characterized comorbid anxiety. In that context, we conducted an additional analysis by identifying, among others, potential primary diagnosis of anxiety disorder (characterized comorbid anxiety) based on treatment associations while seeking not to exclude symptomatic treatment for isolated anxiety episode.

In our study, we found that almost 7.8% of TRD patients were prescribed AD holding anxiety disorders indication with anxiolytics on top, which suggest that these patients may be potentially treated for anxious disorder as primary diagnosis. On top, 5.6% of patient were prescribed AD monotherapy holding anxiety disorder indication, and 1.6% with cyamemazine on top. In France, cyamemazine is especially used for its anxiolytic and sedative effect in treatment of depression.

Second, our definition of TRD was based on the sequence of AD delivered during a period of maximum 3 months (≥3 deliveries) for the year 2019, so that TRD patients hospitalized for a long period of time may have not been captured in our population. However, long-term hospitalized patients would have been captured with potentialized strategies or a combination of ≥2 or 3 ADs dispensed after a psychiatric hospitalization.

Another potential limitation was the minimum interval of 3 weeks required between two successive sequences of treatment strategy before considering that the treatment strategy may have failed. Although some studies may have used shorter interval, this assumption was based on the French guidelines which recommend waiting 2 to 4 weeks before evaluating treatment efficacy.

Conclusion

In conclusion, this study provides the robust population-based estimates of the prevalence of TRD in the French population. Description of treatment patterns highlight the widespread use of second-generation antipsychotics as potentiator of AD medication complemented with anxiolytics.

References

1. WHO | Regional Office for Africa [Internet]. 2023 [cité 21 déc 2023]. Depression and Other Common Mental Disorders: Global Health Estimates (2017). Disponible sur: https://www.afro.who.int/publications/depression-and-other-common-mental-disorders-global-health-estimates-2017

2. Filipovic-Pierucci A, Samson S, Fagot JP, Fagot-Campagna A. Estimating the prevalence of depression associated with healthcare use in France using administrative databases. BMC Psychiatry. 3 janv 2017;17(1):1.

3. SPF. Prévalence des épisodes dépressifs en France chez les 18-85 ans : résultats du Baromètre santé 2021 [Internet]. [cité 21 déc 2023]. Disponible sur: https://www.santepubliquefrance.fr/import/prevalence-des-episodes-depressifs-en-france-chez-les-18-85-ans-resultats-du-barometre-sante-2021

4. Johnston KM, Powell LC, Anderson IM, Szabo S, Cline S. The burden of treatment-resistant depression: A systematic review of the economic and quality of life literature. J Affect Disord. 1 janv 2019;242:195–210.

5. McLafferty M, Brown N, McHugh R, Ward C, Stevenson A, McBride L, et al. Depression, anxiety and suicidal behaviour among college students: Comparisons pre-COVID-19 and during the pandemic. Psychiatry Res Commun. déc 2021;1(2):100012.

6. McIntyre RS, Alsuwaidan M, Baune BT, Berk M, Demyttenaere K, Goldberg JF, et al. Treatment-resistant depression: definition, prevalence, detection, management, and investigational interventions. World Psychiatry. oct 2023;22(3):394–412.

7. Charpeaud T, Genty JB, Destouches S, Yrondi A, Lancrenon S, Alaïli N, et al. Prise en charge des troubles dépressifs résistants : recommandations françaises formalisées par des experts de l'AFPBN et de la fondation FondaMental. L'Encéphale. 1 sept 2017;43(4, Supplement):S1–24.

8. Masson E. EM-Consulte. [cité 21 déc 2023]. Dépression résistante : les stratégies de potentialisation. Disponible sur: https://www.em-consulte.com/article/1048362

9. Masson E. EM-Consulte. [cité 21 déc 2023]. Dépression résistante : les stratégies de changement et d'association de médicaments antidépresseurs. Disponible sur: https://www.em-consulte.com/article/1048361

10. Mrazek DA, Hornberger JC, Altar CA, Degtiar I. A review of the clinical, economic, and societal burden of treatment-resistant depression: 1996-2013. Psychiatr Serv. 1 août 2014;65(8):977–87.

11. Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. nov 2006;163(11):1905–17.

12. Tuppin P, Rudant J, Constantinou P, Gastaldi-Ménager C, Rachas A, de Roquefeuil L, et al. Value of a national administrative database to guide public decisions: From the système national d'information interrégimes de l'Assurance Maladie (SNIIRAM) to the système national des données de santé (SNDS) in France. Rev Epidemiol Sante Publique. oct 2017;65 Suppl 4:S149–67.

13. Atlas de la santé mentale en France [Internet]. [cité 21 déc 2023]. Disponible sur: https://santementale.atlasante.fr/#c=home

14. Estimation de la population au 1er janvier 2023 | Insee [Internet]. [cité 21 déc 2023]. Disponible sur: https://www.insee.fr/fr/statistiques/1893198

15. Kubitz N, Mehra M, Potluri RC, Garg N, Cossrow N. Characterization of treatment resistant depression episodes in a cohort of patients from a US commercial claims database. PLoS One. 2013;8(10):e76882.

16. Fife D, Feng Y, Wang MYH, Chang CJ, Liu CY, Juang HT, et al. Epidemiology of pharmaceutically treated depression and treatment resistant depression in Taiwan. Psychiatry Res. juin 2017;252:277–83.

17. Gronemann FH, Jorgensen MB, Nordentoft M, Andersen PK, Osler M. Incidence of, Risk Factors for, and Changes Over Time in Treatment-Resistant Depression in Denmark: A Register-Based Cohort Study. J Clin Psychiatry. 29 mai 2018;79(4):17m11845.

18. Bosco-Lévy P, Grelaud A, Blin P, Astruc B, Falissard B, Llorca PM, et al. Treatment resistant depression incidence and prevalence using the French nationwide claims database. Pharmacoepidemiol Drug Saf. févr 2021;30(2):169–77.

19. Conway CR, Gebara MA, Walker MC, Lessov-Schlaggar CN, Janski AM, Chibnall JT, et al. Clinical characteristics and management of treatment-resistant depression. J Clin Psychiatry. nov 2015;76(11):1569–70.

20. Mahlich J, Tsukazawa S, Wiegand F. Estimating Prevalence and Healthcare Utilization for Treatment-Resistant Depression in Japan: A Retrospective Claims Database Study. Drugs Real World Outcomes. mars 2018;5(1):35–43.

21. Al-Harbi KS. Treatment-resistant depression: therapeutic trends, challenges, and future directions. Patient Prefer Adherence. 2012;6:369–88.

22. Seroquel XR - referral | European Medicines Agency [Internet]. [cité 11 janv 2024]. Disponible sur: https://www.ema.europa.eu/en/medicines/human/referrals/seroquel-xr

23. Hepner KA, Rowe M, Rost K, Hickey SC, Sherbourne CD, Ford DE, et al. The effect of adherence to practice guidelines on depression outcomes. Ann Intern Med. 4 sept 2007;147(5):320–9.



Figure 1 Illustration of initiation date for a treatment strategy



Figure 2 Illustration of patient inclusion and exclusion for each strategy

Table 1 - Description of TRD patients <65 years old versus ≥ 65 years old

Variable	< 65 years	≥65 years	TOTAL
	N = 46 835	N = 19 975	N = 66 810
Sex			
Female	28189 (60.2%)	14401 (72.1%)	42590 (63.7%)
Male	18646 (39.8%)	5574 (27.9%)	24220 (36.3%)
Age (Mean, SD)	48.7 (10.9)	75.4 (8.2)	56.7 (15.9)
Median	51.0	73.0	56.0
Q1-Q3	[42.0; 57.0]	[69.0; 81.0]	[46.0; 67.0]
Age group, years			
[18 – 35 [	5893 (12.6%)	-	5893 (8.8%)
[35 – 55 [	24160 (51.6%)	-	24160 (36.2%)
[55 – 65 [	16782 (35.8%)	-	16782 (25.1%)
[65 – 75 [	-	10863 (54.4%)	10863 (16.3%)
[75 – 85 [	-	5779 (28.9%)	5779 (8.6%)
≥ 85	-	3333 (16.7%)	3333 (5.0%)
LTD coverage for depressive disorder	31 839 (68.0%)	11 244 (56.3%)	43083 (64.5%)
Average duration of LTD (years)			
Mean (sd)	8.0 (8.5)	11.4 (10.5)	8.9 (9.2)
Median	5.0	8.0	6.0
Q1-Q3	[2.0; 12.0]	[3.0; 18.0]	[2.0; 13.0]
Psychiatric conditions			
Mental disabilities	1776 (3.8%)	376 (1.9%)	2152 (3.2%)
Severe Addictive disorder	8187 (17.5%)	1249 (6.3%)	9436 (14.1%)
Alcohol	6463 (13.8%)	989 (5.0%)	7452 (11.2%)
Tobacco	2019 (4.3%)	285 (1.4%)	2304 (3.4%)
Cannabis	830 (1.8%)	5 (0.0%)	835 (1.2%)
Other	1843 (3.9%)	97 (0.5%)	1940 (2.9%)
Co-treatment in 2019			
Anxiolytics	19899 (42.5%)	7778 (38.9%)	27677 (41.4%)
Opioids	3848 (8.2%)	1928 (9.7%)	5776 (8.6%)
Alcohol dependance treatment	1496 (3.2%)	159 (0.8%)	1655 (2.5%)
Year of treatment initiation of first AD			
2015 or before	23617 (50.4%)	12684 (63.5%)	36306 (54.3%)
2016	4413 (9.4%)	1731 (8.7%)	6144 (9.2%)
2017	5203 (11.1%)	1901 (9.5%)	7104 (10.6%)
2018	6778 (14.5%)	1986 (9.9%)	8763 (13.1%)
2019	6824 (14.6%)	1677 (8.4%)	8502 (12.7%)
Duration of treatment for the TRD episode[1] (months)			
Mean (sd)	20.4 (13.5)	18.3 (11.5)	19.4 (12.8)
Median	19.0	17.0	18.0
Q1-Q3	[9.0; 32.0]	[12.0; 35.0]	[10.0; 33.0]
Proportion of patients with current episode initiated in 2019 (N, %)	16,387 (35,0%)	2,017 (10,1%)	18,404 (27.5%)

Abbreviations: LTD: Long-term Disease;

[1] Based on AD deliveries: delay between first and last deliveries of the current TRD

Table 2 - Treatment strategies observed at last observed delivery of TRD episode (end of follow-up)

Strategy	< 65 years N = 46 835	≥65 years N = 19 975	TOTAL N = 66 810
AD alone	**14694 (31.4%)**	**6629 (33.2%)**	**21323 (31.9%)**
NSMRI	1501 (3.2%)	750 (3.8%)	2251 (3.4%)
SSRI	5604 (12.0%)	2130 (10.7%)	7734 (11.6%)
Other AD	7589 (16.2%)	3749 (18.8%)	11338 (17.0%)
2 ADs combined or AD + POT	**27494 (58.7%)**	**11695 (58.5%)**	**39189 (58.7%)**
2 ADs combined	2074 (4.4%)	1151 (5.8%)	3225 (4.8%)
AD + antipsychotic	17732 (37.9%)	5945 (29.8%)	23677 (35.4%)
AD + antiepileptic	7688 (16.4%)	4599 (23.0%)	12287 (18.4%)
≥2 ADs combined +/- POT	**4647 (9.9%)**	**1651 (8.3%)**	**6298 (9.4%)**
3 ADs combined	4 (0.0%)	26 (0.1%)	30 (0.0%)
≥2 ADs + antipsychotic	1385 (3.0%)	522 (2.6%)	1907 (2.9%)
≥2 ADs + antiepileptic	553 (1.2%)	314 (1.6%)	867 (1.3%)
Other	2660 (5.7%)	789 (3.9%)	3449 (5.2%)

Table 3 – Molecules observed at last delivery (end of follow-up)

Treatments		< 65 years N = 46 835	≥65 years N=19 975	TOTAL N=66 810
Antidepressant				
NSMRI				
	N06AA02-IMIPRAMINE	13 (0%)	5 (0%)	18 (0%)
	N06AA04-CLOMIPRAMINE	2452 (5,2%)	1066 (5,3%)	3518 (5,3%)
	N06AA06-TRIMIPRAMINE	98 (0.2%)	51 (0,3%)	149 (0,2%)
	N06AA09-AMITRIPTYLINE	2540 (5.4%)	1141 (5,7%)	3681 (5,5%)
	N06AA12-DOXEPIN	93 (0.2%)	47 (0,2%)	140 (0,2%)
	N06AA16-DOSULEPIN	249 (0.5%)	144 (0,7%)	393 (0,6%)
	N06AA17-AMOXAPINE	29 (0.1%)	33 (0,2%)	62 (0,1%)
	N06AA21-MAPROTILINE	61 (0.1%)	44 (0,2%)	105 (0,2%)
SSRI				
	N06AB03-FLUOXETINE	4613 (9.8%)	1429 (7,2%)	6042 (9,0 %)
	N06AB04-CITALOPRAM	755 (1.6%)	498 (2,5%)	1253 (1,9%)
	N06AB05-PAROXETINE	6474 (13.8%)	2634 (13,2%)	9108 (13,6%)
	N06AB06-SERTRALINE	4428 (9.5%)	1343 (6,7%)	5771 (8,6%)
	N06AB08-FLUVOXAMINE	132 (0.3%)	64 (0,3%)	196 (0,3%)
	N06AB10-ESCITALOPRAM	4529 (9.7%)	2134 (10,7%)	6663 (10,0%)
MAOI				
	N06AG02-MOCLOBEMIDE	104 (0.2%)	82 (0,4%)	186 (0,3%)
OTHER AD				
	N06AX03-MIANSERIN	2757 (5.9%)	2552 (12,8%)	5309 (8,0%)
	N06AX11-MIRTAZAPINE	4760 (10.2%)	2718 (13,6%)	7478 (11,2%)
	N06AX14-TIANEPTINE	103 (0.2%)	79 (0,4%)	182 (0,3%)
	N06AX16-VENLAFAXINE	10367 (22.1%)	3697 (18,5%)	14064 (21,1%)
	N06AX17-MILNACIPRAN	296 (0.6%)	101 (0,5%)	397 (0,6%)
	N06AX21-DULOXETINE	3452 (7.4%)	1444 (7,2%)	4896 (7,3%)
	N06AX22-AGOMELATINE	260 (0.6%)	76 (0,4%)	336 (0,5%)
	N06AX26-VORTIOXETINE	2605 (5.6%)	700 (3,5%)	3305 (4,9%)
Antipsychotics				
	N05AA06-CYAMEMAZINE	5865 (12.5%)	2049 (10,3%)	7914 (11,8%)
	N05AH03-OLANZAPINE	2833 (6%)	1341 (6,7%)	4174 (6,2%)
	N05AH04-QUETIAPINE	4958 (10.6%)	1216 (6,1%)	6174 (9,2%)
	N05AL05-AMISULPRIDE	868 (1.9%)	252 (1,3%)	1120 (1,7%)
	N05AX08-RISPERIDONE	2404 (5.1%)	1323 (6,6%)	3727 (5,6%)
	N05AX12-ARIPIPRAZOLE	3921 (8.4%)	815 (4,1%)	4736 (7,1%)
Other				
	N05AN01-LITHIUM	904 (1.9%)	244 (1,2%)	1148 (1,7%)
Antiepileptic Drugs				
	N03AA02-PHENOBARBITAL	316 (0.7%)	278 (1,4%)	594 (0,9%)
	N03AA03-PRIMIDONE	15 (0%)	37 (0,2%)	52 (0,1%)
	N03AB02-PHENYTOIN	17 (0%)	13 (0,1%)	30 (0%)
	N03AE01-CLONAZEPAM	229 (0.5%)	142 (0,7%)	371 (0,6%)
	N03AF01-CARBAMAZEPINE	1037 (2.2%)	549 (2,7%)	1586 (2,4%)
	N03AF02-OXCARBAZEPINE	275 (0.6%)	103 (0,5%)	378 (0,6%)
	N03AF03-RUFINAMIDE	1 (0%)	-	1 (0%)
	N03AF04-ESLICARBAZEPINE	11 (0%)	-	11 (0%)
	N03AG01-VALPROIC ACID	2663 (5.7%)	1234 (6,2%)	3897 (5,8%)
	N03AG02-VALPROMIDE	876 (1.9%)	611 (3,1%)	1487 (2,2%)
	N03AG04-VIGABATRIN	1 (0%)	1 (0%)	2 (0%)
	N03AX09-LAMOTRIGINE	3745 (8%)	1454 (7,3%)	5199 (7,8%)
	N03AX11-TOPIRAMATE	642 (1.4%)	150 (0,8%)	792 (1,2%)
	N03AX14-LEVETIRACETAM	839 (1.8%)	967 (4,8%)	1806 (2,7%)
	N03AX15-ZONISAMIDE	46 (0.1%)	16 (0,1%)	62 (0,1%)
	N03AX17-STIRIPENTOL	2 (0%)	-	2 (0%)
	N03AX18-LACOSAMIDE	159 (0.3%)	124 (0,6%)	283 (0,4%)
	N03AX22-PERAMPANEL	24 (0.1%)	8 (0 %)	32 (0,05%)

Table 4 – Patients probably treated for other primary diagnosis than MDD

Strategy	< 65 years N = 46 835	≥65 years N = 19 975	TOTAL N = 66 810
Patients probably treated for other primary diagnosis	**11386 (24.3%)**	**4373 (21.9%)**	**15759 (23.6%)**
Anxiety disorder	**6790 (14.5%)**	**2552 (12.8%)**	**9342 (14%)**
AD with anxiety disorder indication (monotherapy)	2725 (5.8%)	1039 (5.2%)	3764 (5.6%)
AD with anxiety disorder indication (mono) + anxiolytic	3228 (6.9%)	1269 (6.4%)	4497 (6.7%)
≥ 1 AD with anxiety disorder indication + cyamemazine	249 (0.5%)	71 (0.4%)	320 (0.5%)
≥ 1 AD with anxiety disorder indication + cyamemazine + anxiolytics	588 (1.3%)	173 (0.9%)	761 (1.1%)
Neuropathic pain	**3848 (8.2%)**	**1928 (9.7%)**	**5776 (8.6%)**
AD + opioid	812 (1.7%)	424 (2.1%)	1236 (1.9%)
≥ 1 AD + POT + opioid	3036 (6.5%)	1504 (7.5%)	4540 (6.8%)
Alcohol dependency	**1496 (3.2%)**	**159 (0.8%)**	**1655 (2.5%)**
AD + nalmefene	318 (0.7%)	35 (0.2%)	353 (0.5%)
≥ 1 AD + POT + nalmefene	1178 (2.5%)	124 (0.6%)	1302 (1.9%)